CI

At a glance

ClinicalIndex Comparison Record
Phase 2Active· 10 enrolled
Drug / intervention
Evolocumab +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT06284564
NCT06284564Phase 2Active
CompareCT.gov

A Phase II Study Bolstering Outcomes by Optimizing Immunotherapy Strategies With Evolocumab and Nivolumab in Patients With Metastatic Renal Cell Carcinoma (BOOST-RCC)

M.D. Anderson Cancer Center·interventional·Posted Feb 29, 2024·Updated Apr 21, 2026

In Brief

A Phase 2 clinical trial evaluating Evolocumab and Nivolumab for Metastatic Renal Cell Carcinoma. Active but no longer recruiting, targeting 10 participants across 2 sites.

Detailed Summary

To learn if evolocumab and nivolumab can control metastatic and refractory renal cell carcinoma. The safety of this drug combination will also be studied.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsMetastatic Renal Cell Carcinoma
CountriesUnited States
CollaboratorsBristol-Myers Squibb, Cancer Prevention Research Institute of Texas, United States Department of Defense

Timeline

Phase 2Active
20252026
First PostedFeb 29, 2024
Enrollment StartAug 7, 2024
Primary CompletionOct 1, 2026
TodayJul 1, 2026
Enrollment to primary: 2.1 yearsPosted 2.3 years agoPrimary completion in 3 months

Interventions

Evolocumabdrug

Given by SC

Nivolumabdrug

Given by IV